Home/Filings/4/0000905718-19-000260
4//SEC Filing

Ferguson James J. III 4

Accession 0000905718-19-000260

CIK 0001582554other

Filed

Feb 26, 7:00 PM ET

Accepted

Feb 27, 4:58 PM ET

Size

5.8 KB

Accession

0000905718-19-000260

Insider Transaction Report

Form 4
Period: 2019-02-25
Ferguson James J. III
Chief Medical Officer
Transactions
  • Award

    Stock option (right to buy)

    2019-02-25+350,000350,000 total
    Exercise: $1.09Exp: 2029-02-24Common Stock (350,000 underlying)
Footnotes (1)
  • [F1]The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests as to 25% of the shares on February 25, 2020 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on March 31, 2020. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

Issuer

Matinas BioPharma Holdings, Inc.

CIK 0001582554

Entity typeother

Related Parties

1
  • filerCIK 0001769041

Filing Metadata

Form type
4
Filed
Feb 26, 7:00 PM ET
Accepted
Feb 27, 4:58 PM ET
Size
5.8 KB